Mike Cohen
banner
michaelnadbio.bsky.social
Mike Cohen
@michaelnadbio.bsky.social
Chemical biologist passionate about post-translational modifications (PTMs) and a keen interest in drug development. Professor at OHSU leading a team dedicated to unraveling the mysteries of PARPs and ADP-ribosylation.
Congrats Karolin for this well deserved award!
February 3, 2026 at 1:49 AM
very cool, team Balyn-congrats!
January 6, 2026 at 11:12 PM
Congrats!
December 6, 2025 at 2:55 AM
Happy to have made a small contribution during my mini-sabbatical in @ladurner.bsky.social lab!
November 13, 2025 at 6:42 PM
They demonstrate that a common PARP1 variant (V762) shifts talazoparib from a non-retentive (Type II) to an allosteric, pro-retention (Type I) mode, thereby boosting chromatin trapping and cancer cell killing. The finding makes a strong case for genotype-guided dosing in HRD cancer therapy.
November 13, 2025 at 6:42 PM
Congrats Jeremy! Well-deserved!
July 10, 2025 at 2:15 AM
Exciting times in the fields of ADP-ribosylation and ubiquitylation!
July 9, 2025 at 4:15 PM
This paper, coupled with an exciting new paper from @ahellab.bsky.social and the Van Der Heiden Van Noort groups: www.nature.com/articles/s41...

And our recent collaborative work with @jnpruneda.bsky.social team: www.biorxiv.org/content/10.1...

reveal RNF114 as a reader and writer of MARUbylation.
July 9, 2025 at 4:15 PM